Science

Taha Koray Sahin: Our Study on the Albumin-Myosteatosis Gauge as a Prognostic Biomarker in ICI-Treated Patients is Now Out

Taha Koray Sahin/X

Jun 29, 2025, 06:13

Taha Koray Sahin: Our Study on the Albumin-Myosteatosis Gauge as a Prognostic Biomarker in ICI-Treated Patients is Now Out

Taha Koray Sahin, Medical Oncologist at Hacettepe University, shared a post on X:

“Our latest study is now out in Immunotherapy!

The albumin–myosteatosis gauge (AMG) is an independent prognostic biomarker in ICI-treated patients

Low AMG is associated with shorter PFS and OS

A practical, accessible, and promising biomarker

Title: Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors

Authors: Taha Koray Sahin, Deniz Can Guven, Yakup Ozbay, Firat Atak, Sevtap Arslan, Mehmet Cihan İcli, Latif Karahan, Yunus Kaygusuz, Zafer Arik, Omer Dizdar, Mustafa Erman, Suayib Yalcin, Mehmet Ruhi Onur, Sercan Aksoy

You can read the Full Article on Immunotherapy

Taha Koray Sahin: Our Study on the Albumin-Myosteatosis Gauge as a Prognostic Biomarker in ICI-Treated Patients is Now Out

More posts featuring Immune checkpoint inhibitors.

Albumin-Myosteatosis Gauge biomarker cancer Deniz Can Guven Firat Atak Immune Checkpoint Inhibitors immunotherapy Latif Karahan Mehmet Cihan İcli Mehmet Ruhi Onur Mustafa Erman Ömer Dizdar OncoDaily Oncology Sercan Aksoy Sevtap Arslan Suayib Yalcin Taha Koray Sahin Yakup Ozbay Yunus Kaygusuz Zafer Arik

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025